Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trialSteven M. Horwitz, June Weon Cheong, Michelle A. Fanale et al.|The Lancet|2018Cited by 733
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trialJoshua Brody, Raúl Córdoba, Judit Jørgensen et al.|Blood|2025Cited by 56